Please note: AABB reserves the right to make updates to this program.
Live Program Date: Thursday, June 30, 2022 - On-Demand Available
Program Number: 22EL-748
This on-demand hot topic discussion is complimentary to all but registration is required. After signing up on GoToWebinar the video will immediately begin to play.
Faculty responses to your questions during the live program can be found on the GoToWebinar platform or you can view them here.
Approximately seven million (or 2.7%) US adults are immunocompromised and are therefore more likely to experience severe and prolonged illness from COVID-19 infection, with limited treatment options. Evidence suggests that treatment with high-titer CCP may provide an effective therapeutic alternative in this patient population when other options have proven to be ineffective. Join experts as they discuss the data around the use of high-titer CCP collected from donors with recent breakthrough COVID-19 infections. Which patients can most benefit from this therapy and how? How effective is the treatment with CCP as compared to other therapies? A discussion will also address the FDA permitted use and current guidance. An extended question and answer period will follow brief presentations.
After participating in this educational activity, participants should be able to:
Moderator: Nigel Paneth, MD, MPH, University Distinguished Professor, Emeritus, Departments of Epidemiology & Biostatistics and Pediatrics & Human Development, College of Human Medicine, Michigan State University
Panel Members:
Continuing education credit will not be offered for this program.